Parsons James T. - 01 Jun 2026 Form 4 Insider Report for DiaMedica Therapeutics Inc. (DMAC)

Reporting relationship
Director
Issuer ticker
DMAC
Reported as of
01 Jun 2026
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
03 Jun 2026, 17:24:25 UTC
Prior SEC filing
13 Mar 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Joshua L. Colburn, attorney-in-fact

Key filing fact

Parsons James T. filed Form 4 for DiaMedica Therapeutics Inc. (DMAC) on 03 Jun 2026.

Key facts

  • This page summarizes Parsons James T.'s Form 4 filing for DiaMedica Therapeutics Inc. (DMAC).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 03 Jun 2026, 17:24.

Change

  • Previous filing in this sequence was filed on 13 Mar 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001759855 Primary reporting owner

Parsons James T.

Relationship
Director
Address
301 CARLSON PARKWAY, SUITE 210, MINNEAPOLIS
Signature
/s/ Joshua L. Colburn, attorney-in-fact
Signature date
03 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DMAC transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares
+51,189
Change %
Price
$0.000000*
Shares after
51,189
Date
01 Jun 2026
Ownership
Direct
Underlying class
Voting Common Shares
Underlying amount
51,189
Exercise price
$5.84
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Scheduled to vest in four substantially equal quarterly installments.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .